vs
CASTLE BIOSCIENCES INC（CSTL）与RMR GROUP INC.（RMR）财务数据对比。点击上方公司名可切换其他公司
CASTLE BIOSCIENCES INC的季度营收约是RMR GROUP INC.的1.3倍（$87.0M vs $66.7M），RMR GROUP INC.同比增速更快（40.8% vs 0.8%）
Castle Biosciences是一家处于商业阶段的诊断企业，专注于开发和商业化针对黑色素瘤等皮肤癌及罕见病的专利临床诊断检测产品，主要服务美国医疗市场，聚焦未被满足的精准诊断需求领域，辅助临床医生制定治疗决策。
RMR集团是总部位于美国的另类资产管理企业，核心业务聚焦不动产及相关投资，覆盖商业地产、住宅物业、基础设施等赛道，服务全球核心市场的机构投资者、高净值人士及零售客户。
CSTL vs RMR — 直观对比
营收规模更大
CSTL
是对方的1.3倍
$66.7M
营收增速更快
RMR
高出40.0%
0.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $87.0M | $66.7M |
| 净利润 | — | $12.2M |
| 毛利率 | 79.0% | — |
| 营业利润率 | -4.4% | 48.1% |
| 净利率 | — | 18.3% |
| 营收同比 | 0.8% | 40.8% |
| 净利润同比 | — | 91.1% |
| 每股收益（稀释后） | $-0.06 | $0.71 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSTLRMR
| Q4 25 | $87.0M | $66.7M | ||
| Q3 25 | $83.0M | — | ||
| Q2 25 | $86.2M | — | ||
| Q1 25 | $88.0M | — | ||
| Q4 24 | $86.3M | — | ||
| Q3 24 | $85.8M | — | ||
| Q2 24 | $87.0M | — | ||
| Q1 24 | $73.0M | — |
净利润CSTLRMR
| Q4 25 | — | $12.2M | ||
| Q3 25 | $-501.0K | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-25.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $8.9M | — | ||
| Q1 24 | $-2.5M | — |
毛利率CSTLRMR
| Q4 25 | 79.0% | — | ||
| Q3 25 | 77.5% | — | ||
| Q2 25 | 79.5% | — | ||
| Q1 25 | 81.4% | — | ||
| Q4 24 | 81.3% | — | ||
| Q3 24 | 81.8% | — | ||
| Q2 24 | 83.3% | — | ||
| Q1 24 | 81.0% | — |
营业利润率CSTLRMR
| Q4 25 | -4.4% | 48.1% | ||
| Q3 25 | -8.2% | — | ||
| Q2 25 | -4.9% | — | ||
| Q1 25 | -31.7% | — | ||
| Q4 24 | 4.7% | — | ||
| Q3 24 | 5.9% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | -7.5% | — |
净利率CSTLRMR
| Q4 25 | — | 18.3% | ||
| Q3 25 | -0.6% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | -29.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.6% | — | ||
| Q2 24 | 10.3% | — | ||
| Q1 24 | -3.5% | — |
每股收益（稀释后）CSTLRMR
| Q4 25 | $-0.06 | $0.71 | ||
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $0.15 | — | ||
| Q1 25 | $-0.90 | — | ||
| Q4 24 | $0.32 | — | ||
| Q3 24 | $0.08 | — | ||
| Q2 24 | $0.31 | — | ||
| Q1 24 | $-0.09 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $299.5M | $49.3M |
| 总债务越低越好 | $10.1M | — |
| 股东权益账面价值 | $470.9M | $232.7M |
| 总资产 | $578.6M | $687.1M |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资CSTLRMR
| Q4 25 | $299.5M | $49.3M | ||
| Q3 25 | $287.5M | — | ||
| Q2 25 | $275.9M | — | ||
| Q1 25 | $275.2M | — | ||
| Q4 24 | $293.1M | — | ||
| Q3 24 | $95.0M | — | ||
| Q2 24 | $85.6M | — | ||
| Q1 24 | $82.9M | — |
总债务CSTLRMR
| Q4 25 | $10.1M | — | ||
| Q3 25 | $10.0M | — | ||
| Q2 25 | $10.0M | — | ||
| Q1 25 | $10.0M | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | $10.0M | — | ||
| Q2 24 | $10.0M | — | ||
| Q1 24 | $10.0M | — |
股东权益CSTLRMR
| Q4 25 | $470.9M | $232.7M | ||
| Q3 25 | $467.0M | — | ||
| Q2 25 | $455.4M | — | ||
| Q1 25 | $440.3M | — | ||
| Q4 24 | $455.8M | — | ||
| Q3 24 | $441.1M | — | ||
| Q2 24 | $423.9M | — | ||
| Q1 24 | $402.5M | — |
总资产CSTLRMR
| Q4 25 | $578.6M | $687.1M | ||
| Q3 25 | $562.8M | — | ||
| Q2 25 | $544.7M | — | ||
| Q1 25 | $501.7M | — | ||
| Q4 24 | $531.2M | — | ||
| Q3 24 | $514.6M | — | ||
| Q2 24 | $487.3M | — | ||
| Q1 24 | $458.5M | — |
负债/权益比CSTLRMR
| Q4 25 | 0.02× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | 0.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $26.9M | $10.7M |
| 自由现金流经营现金流 - 资本支出 | $19.7M | — |
| 自由现金流率自由现金流/营收 | 22.7% | — |
| 资本支出强度资本支出/营收 | 8.3% | — |
| 现金转化率经营现金流/净利润 | — | 0.88× |
| 过去12个月自由现金流最近4个季度 | $28.3M | — |
8季度趋势，按日历期对齐
经营现金流CSTLRMR
| Q4 25 | $26.9M | $10.7M | ||
| Q3 25 | $22.6M | — | ||
| Q2 25 | $20.8M | — | ||
| Q1 25 | $-6.0M | — | ||
| Q4 24 | $24.4M | — | ||
| Q3 24 | $23.3M | — | ||
| Q2 24 | $24.0M | — | ||
| Q1 24 | $-6.8M | — |
自由现金流CSTLRMR
| Q4 25 | $19.7M | — | ||
| Q3 25 | $7.8M | — | ||
| Q2 25 | $11.6M | — | ||
| Q1 25 | $-10.8M | — | ||
| Q4 24 | $16.8M | — | ||
| Q3 24 | $17.0M | — | ||
| Q2 24 | $18.8M | — | ||
| Q1 24 | $-16.0M | — |
自由现金流率CSTLRMR
| Q4 25 | 22.7% | — | ||
| Q3 25 | 9.4% | — | ||
| Q2 25 | 13.4% | — | ||
| Q1 25 | -12.2% | — | ||
| Q4 24 | 19.5% | — | ||
| Q3 24 | 19.8% | — | ||
| Q2 24 | 21.6% | — | ||
| Q1 24 | -21.9% | — |
资本支出强度CSTLRMR
| Q4 25 | 8.3% | — | ||
| Q3 25 | 17.9% | — | ||
| Q2 25 | 10.7% | — | ||
| Q1 25 | 5.4% | — | ||
| Q4 24 | 8.8% | — | ||
| Q3 24 | 7.4% | — | ||
| Q2 24 | 6.0% | — | ||
| Q1 24 | 12.5% | — |
现金转化率CSTLRMR
| Q4 25 | — | 0.88× | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.60× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.29× | — | ||
| Q2 24 | 2.69× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSTL
| Dermatologic | $48.6M | 56% |
| Non Dermatologic | $38.4M | 44% |
RMR
| Management Service Incentive | $23.6M | 35% |
| Industrial Logistics Properties Trust | $15.1M | 23% |
| Managed Private Real Estate Capital | $11.1M | 17% |
| Office Properties Income Trust | $5.6M | 8% |
| Other Private Entities | $5.3M | 8% |
| RMR Residential | $3.4M | 5% |
| Sonesta International Hotels Corporation | $2.1M | 3% |
| Investment Advisory Management And Administrative Service | $1.2M | 2% |
